Immune Pharmaceuticals - Company & Market Research Reports

Immune Pharmaceuticals is a clinical stage biopharmaceutical company that develops novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company's lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.

From
Atopic Dermatitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Atopic Dermatitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 379 Pages
From
From
From
From
Psoriasis - Pipeline Review, H2 2018 - Product Thumbnail Image

Psoriasis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 726 Pages
From
Psoriasis - Pipeline Review, H1 2018 - Product Thumbnail Image

Psoriasis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 709 Pages
From
From
From
From
Global Analgesics Market 2016-2020 - Product Thumbnail Image

Global Analgesics Market 2016-2020

  • Report
  • 102 Pages
From
Bullous Pemphigoid - Pipeline Review, H1 2018 - Product Thumbnail Image

Bullous Pemphigoid - Pipeline Review, H1 2018

  • Drug Pipelines
  • 66 Pages
From
From
Low Back Pain - Pipeline Review, H2 2018 - Product Thumbnail Image

Low Back Pain - Pipeline Review, H2 2018

  • Drug Pipelines
  • 113 Pages
From
Low Back Pain - Pipeline Review, H1 2018 - Product Thumbnail Image

Low Back Pain - Pipeline Review, H1 2018

  • Drug Pipelines
  • 105 Pages
From
From
Neuropathic Pain - Pipeline Review, H2 2017 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H2 2017

  • Drug Pipelines
  • 488 Pages
From
Neuropathic Pain - Pipeline Review, H1 2017 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H1 2017

  • Drug Pipelines
  • 485 Pages
From
From
Loading Indicator
adroll